Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients.

Jean Claude AlvarezPierre MoineBenjamin DavidoIsabelle EttingDjillali AnnaneIslam Amine LarabiNicolas Simonnull null

Published in: European journal of clinical pharmacology (2020)

According to the estimated 50% effective concentration of lopinavir against SARS-CoV-2 virus in Vero E6 cells (16.7 mg/L), our model showed that at steady state, a dose of 400 mg b.i.d. led to 40% of patients below the minimum effective concentration while a dose of 1200 mg b.i.d. will reduce this proportion to 22%.

Keyphrases

sars cov
end stage renal disease
ejection fraction
induced apoptosis
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
cell cycle arrest
respiratory syndrome coronavirus
oxidative stress
cell death
signaling pathway